Cargando…

Clinical Evaluation of an Investigational 5 mL Wearable Injector in Healthy Human Subjects

An investigational wearable injector (WI), the BD Libertas Wearable Injector (BD Libertas is a trademark of Becton, Dickinson and Company), was evaluated in an early feasibility clinical study for functional performance, tissue effects, subject tolerability, and acceptability of 5 mL, non‐Newtonian...

Descripción completa

Detalles Bibliográficos
Autores principales:	Woodley, Wendy D., Yue, Wen, Morel, Didier R., Lainesse, Audrey, Pettis, Ronald J., Bolick, Natasha G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8212760/ https://www.ncbi.nlm.nih.gov/pubmed/33278331 http://dx.doi.org/10.1111/cts.12946

Ejemplares similares

Clinical evaluation of large volume subcutaneous injection tissue effects, pain, and acceptability in healthy adults
por: Woodley, Wendy D., et al.
Publicado: (2021)

Imaging of large volume subcutaneous deposition using MRI: exploratory clinical study results
por: Pettis, Ronald J., et al.
Publicado: (2023)

Closed-loop wearable naloxone injector system
por: Chan, Justin, et al.
Publicado: (2021)

Reliability of the 100 mL water swallow test in patients with head and neck cancer and healthy subjects
por: Vermaire, Jorine A., et al.
Publicado: (2021)

Ease of Use of the Insulin Glargine 300 U/mL Pen Injector in Insulin-Naïve People With Type 2 Diabetes
por: Pohlmeier, Harald, et al.
Publicado: (2017)

Investigation of the ANKA Injector
por: Praestegaard, L, et al.
Publicado: (2001)

A proposed injector for the LCLS linac
por: Yeremian, A D, et al.
Publicado: (1998)

Formative Study on the Wearability and Usability of a Large-Volume Patch Injector
por: Lange, Jakob, et al.
Publicado: (2021)

Bioavailability study of Enoxaparin Sodium Chemi (80 mg/0.8 mL) and Clexane (80 mg/0.8 mL) subcutaneous injection in healthy adults
por: Febbraro, Salvatore, et al.
Publicado: (2021)

The NLC Injector System
por: Bharadwaj, V K, et al.
Publicado: (1999)

Pharmacokinetic and pharmacodynamic bioequivalence between regular human insulin (rDNA origin) in 0.9% sodium chloride ready‐to‐use infusion 1 U/mL and 100 U/mL concentrate diluted to 1 U/mL in healthy males
por: Hompesch, Marcus, et al.
Publicado: (2021)

Novel cannula design improves large volume auto-injection rates for high viscosity solutions
por: Roberts, Bruce C., et al.
Publicado: (2021)

Evaluation of performance, acceptance, and compliance of an auto-injector in healthy and rheumatoid arthritic subjects measured by a motion capture system
por: Xiao, Xiao, et al.
Publicado: (2018)

Randomised, phase I pharmacokinetic study of adalimumab biosimilar CT‐P17 (40 mg/0.4 mL) by autoinjector and prefilled syringe in healthy subjects
por: Davidson, Antonia, et al.
Publicado: (2021)

An investigation of space charge effects for the Booster injector to the CPS
por: Morton, P L
Publicado: (1968)

Investigation of TTF injector alignment with the simulation Code V
por: Beinhauer, W, et al.
Publicado: (2001)

Beam dynamics investigation of the first tank of a 70 mA CH-DTL proton injector
por: Clemente, G F, et al.
Publicado: (2005)

Bioequivalence and comparative pharmacodynamics of insulin lispro 200 U/mL relative to insulin lispro (Humalog®) 100 U/mL
por: de la Peña, Amparo, et al.
Publicado: (2015)

Performance of 3 mL versus 5 mL Discarded Volume for Blood Sampling from Central Venous Access Device
por: Lalthanthuami, HT, et al.
Publicado: (2021)

Update to the NLC Injector System Design
por: Sheppard, J C, et al.
Publicado: (2001)

Reliability and validity of measuring respiration movement using a wearable strain sensor in healthy subjects
por: Liu, Haijuan, et al.
Publicado: (2017)

Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml
por: Steinstraesser, A, et al.
Publicado: (2014)

THU073 Somapacitan Administered Subcutaneously At 5 mg/1.5 mL Or 10 mg/1.5 mL Strengths Yields Clinically Similar PK And IGF-I Profiles In Healthy Participants
por: Rasmussen, Michael Højby, et al.
Publicado: (2023)

AbobotulinumtoxinA provides flexibility for the treatment of cervical dystonia with 500 U/1 mL and 500 U/2 mL dilutions
por: Lew, Mark F., et al.
Publicado: (2021)

The chain of LEP injectors: LEP Injector Study Group
Publicado: (1983)

Efficacy and Safety of Insulin Glargine 300 U/mL versus 100 U/mL in Diabetes Mellitus: A Comprehensive Review of the Literature
por: Vargas-Uricoechea, Hernando
Publicado: (2018)

In Silico Head-to-Head Comparison of Insulin Glargine 300 U/mL and Insulin Degludec 100 U/mL in Type 1 Diabetes
por: Schiavon, Michele, et al.
Publicado: (2020)

AbobotulinumtoxinA using 2-mL dilution (500 U/2-mL) maintains durable improvement across multiple treatment cycles
por: Dashtipour, Khashayar, et al.
Publicado: (2020)

Measurement of the kaon mass difference $m_L -m_S$ by the two regenerator method
por: Geweniger, C, et al.
Publicado: (1974)

Beams in the injectors
por: Bartosik, H, et al.
Publicado: (2014)

The Linear Injector
por: Klein, H
Publicado: (1988)

Pre-injectors
por: Huguenin, J, et al.
Publicado: (1970)

Injector for LEP
por: Brunet, P, et al.
Publicado: (1979)

The Berkeley injector
por: Rutkowski, H L, et al.
Publicado: (1992)

Investigation of the spray formation and breakup process in an open-end swirl injector
por: Chen, Chen, et al.
Publicado: (2020)

Yandex and ML
por: Ustyuzhanin, Andrey
Publicado: (2017)

Nvidia and ML
por: Altoe, Piero
Publicado: (2017)

Intel and ML
por: Pabst, Hans
Publicado: (2017)

TinyML
por: Warden, Pete
Publicado: (2019)

ML in LHCb
por: Nolte, Niklas Stefan
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_5gooi7u28k201gv3g7hfjcu5h5